Company Name | Novartis (Taiwan) Co., Ltd. |
---|---|
Protocol Number | CERL080ATW12 |
Title of Study | Evaluating the Safety of Myfortic (Mycophenolate sodium) in patients with Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan population |
Primary Objective | To describe the safety profile of EC-MPS on LN patients |
Number of Sites | 6 |
Period of Study | From:16-Mar-2021 to:31-Mar-2024 |
Number of Patients | 64人 |
IRB Approval Date | 26-Nov-2020 |
Publication Plan / Date | 31-Mar-2025 |